Advanced Cancer Clinical Trial
Official title:
Individual Dose-escalated Bi-daily sc Ghrelin in Cancer Cachexia: a Phase I/II Study
Verified date | July 2017 |
Source | Cantonal Hospital of St. Gallen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cachexia, a condition of severe malnutrition, negative nitrogen balance, muscle wasting,
weight loss, and anorexia, is a frequent affecting more than 80% of patients in advanced
cancer disease causing a high burden on patients and their families. Nutritional,
pharmacological, and behavioural interventions for cancer-related ACS and associated symptoms
have, despite the importance for cancer care, limited effect on only a minority of patients.
New strategies are required.
Ghrelin, a 28 amino acid peptide discovered in 1999, is predominantly secreted by gastric
endocrine cells and is an endogenous ligand for the growth hormone secretagogue (GHS)
receptor. When administered peripherally it stimulates growth hormone secretion, food intake,
triggers a positive energy balance, produces weight gain through a central mechanism
involving hypothalamic neuropeptides and has anti-inflammatory effects. A recently completed
trial on intravenous ghrelin in advanced cancer patients with ACS reports good tolerability
and safety of single intravenous application of 2 and 8μg/kg Ghrelin.
Given the facts that ACS is a major burden in patients suffering advanced cancer disease and
ghrelin is a major signal for stimulating food intake, promoting positive energy balance and
weight gain and may have anti-inflammatory effect it remains to be determined whether the
administration of ghrelin will have a positive clinical effect on cancer anorexia/ cachexia
syndrome ACS. The next logical clinical development step is a proper dose-finding study of
twice daily subcutaneous administration and proof-of-concept of main outcomes.
Status | Completed |
Enrollment | 21 |
Est. completion date | December 2011 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion: - Age: Patients must be older than 18 years of age - Tumour situation: Patients with any type of advanced (defined as locally recurrent or metastatic), incurable solid tumour. - Cachexia: defined as involuntary loss of weight of =2% in 2 months or =5% in 6 months, and ongoing in the last 4 weeks - No simple starvation: Patients must be able to eat, defined as no severe structural barriers in the upper gastrointestinal tract and no bowel obstruction. - No late cachexia: Patient must have an expected life expectancy > 3 months - No anti-cachexia or appetite-stimulating medications: Patients are not allowed to have corticosteroids unless for maximum 2 days for chemotherapy, no progestin therapy within the last 2 weeks, no anabolic drugs within the last month. Prokinetic medication, NSAR (paracetamol and novamin sulphate are allowed, if given in a fixed dose for two weeks before visit 1, and expected to be given during the whole trial period. - Laboratory test results within these ranges: Absolute neutrophil count = 1.5 x 109/L, platelet count = 100 x 109/L, serum creatinine = 2.0 mg/dL (177 µmol/L), creatinine clearance ClCr = 50ml/min, total bilirubin =1.5 mg/dL (25µmol/L), and AST (SGOT)/ ALT (SGPT) =2 x ULN or if hepatic metastases are present = 5 x ULN. - No other trial: Patient is not or was not participating in any other clinical trial within 28 before visit 2. - Women of childbearing potential: A negative pregnancy test & effective contraception are mandatory in child-bearing age. - Men agree not to father a child (i.e. use adequate birth control if sexually active) during participation in the trial. - Cognition: Presence of a normal level of consciousness (mandatory is a normal abbreviated screening mini-mental test or a common mini-mental = 27/30; in elderly patients age = 65 years or patients with low education a mini mental status of =25/30 points will be considered adequate). - Consent: The patient has voluntarily signed and dated an independent Ethics Committee (IEC) approved consent prior to any study-specific procedures. - Gastrectomy: Patients with history of gastrectomy are eligible. Exclusion: - Questionnaires: Any psychiatric disorder, alcohol and illicit drug abuser language problem that would prevent the patient from filling in the questionnaires adequately. - Patient with a history of psychiatric diagnosis of depression or clinical diagnosis of depression as determined by the treating physician or Hospital Anxiety Depression Scale total score of 13 or greater. - History of alcohol abuse as determined by the CAGE questionnaire (=2/4) or history of illicit drug abuse within last 12 months. - Parenteral nutrition - Diabetes mellitus with secondary organ dysfunction: coronary heart disease, previous stroke, renal insufficiency - Patients with cerebral metastases or prophylactic whole brain irradiation for possible cerebral metastases. - Known hypersensitivity to ghrelin. - Known infection with HIV or a viral hepatitis - Patients with known myeloid malignancy or tumours having bone marrow involvement - Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. - Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. |
Country | Name | City | State |
---|---|---|---|
Switzerland | Cantonal Hospital St. Gallen KSSG | St. Gallen |
Lead Sponsor | Collaborator |
---|---|
Cantonal Hospital of St. Gallen | Bachem |
Switzerland,
Strasser F, Lutz TA, Maeder MT, Thuerlimann B, Bueche D, Tschöp M, Kaufmann K, Holst B, Brändle M, von Moos R, Demmer R, Cerny T. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer. 2008 Jan 29;98(2):300-8. doi: 10.1038/sj.bjc.6604148. Epub 2008 Jan 8. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To assess the dose of ghrelin in tumour patients with ACS causing optimal stimulation of nutritional intake - minimal dose for maximal nutritional intake (MD-MANI) - or the maximally tolerable dose (MTD), which one occurs first | bi-weekly | ||
Primary | To assess the effect of ghrelin on muscle strength. | weekly | ||
Secondary | To assess the toxicity and tolerability, pharmacokinetics and symptoms of eating of ghrelin. | bi-weekly | ||
Secondary | To assess the effect of ghrelin on muscle mass, physical function, safety, toxicity and tolerability, pharmacokinetics, symptoms of eating, gastrointestinal motility, inflammation | weekly |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 |